Home > Transparency Posts > The Transparency Task Force’s Fifth Question

The Transparency Task Force’s Fifth Question

We want to know how the FDA could provide information to the public to better explain the agency's work and its decisions. The fifth question is:

As FDA becomes more transparent, what information should remain confidential in order to promote key internal and external policy goals, such as preserving patient privacy, and how, in these cases, should FDA explain the importance of confidentiality?

Thank you and we look forward to your input and participation.

FDA Transparency Task Force

  1. Publius
    January 14, 2010 at 10:55 am

    I think that if the FDA is going to state that they are transparent, then they should honestly be transparent. A good example is the issue of REMS where the FDA has, according to information given at a public meeting, established internal sub-teams to work on various related issues, such as prescriber, patient, dispenser and metrics.
    While it is very good that the FDA has these internal sub-teams, they do the public no good at all if we do not know what they are working on, or what their general thinking is.
    Before your question above can be answered, there has to be true transparency. There is an old quote in politics that the two things you never want to see being made are laws and sausages. I think that there is a general feeling that this old adage is not fully correct. The public can greatly benefit from a better understanding of this process.
    Granted, records, such as patient records, should be kept as confidential as possible to comply with HIPAA, but internal policy which directly affects external policy should not be kept behind fully closed doors. The thinking of the FDA influences how pharmaceutical companies and the general public interact with the agency, and it is vitally important that these communications not occur in a vacuum of understanding, bith from the Agency and the outside influences.
    Additionally, if the Agency opens up to become more transparent, especially on the sub-team level, then there is always a chance that both Industry and the Agency can benefit from the mutual understanding which will arise.
    -Publius

  2. làm bằng đại học
    September 27, 2013 at 9:59 am

    I hope that the FDA’s growing social and give lots of useful information

  3. nguyenhoangph
    April 2, 2014 at 2:29 pm

    I agree with Publius, the FDA is going to state that they are transparent, then they should honestly be transparent.

  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 171 other followers

%d bloggers like this: